UNSPSC 51171909: Esomeprazole or omeprazole

This classification denotes a proton pump inhibitor with the molecular formula C17H19N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KG60484QX9, chemically known as 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole but generally known as omeprazole, which bears US NIH Compound Identifier 4594. European Medicines Agency schedules Omeprazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09439MIG. The term OMEPRAZOLE is an International Non-Proprietary Name.

UNSPSC 51171909 Esomeprazole or omeprazole is a Commodity code that reflects state and local government procurement of specific pharmaceutical products — primarily generic proton-pump inhibitors — through both direct specimen-collection drug-testing programs and broader pharmacy benefit and pharmaceutical-distribution contracts. The issuing bodies span county criminal-justice departments, state health and human services agencies, and multi-state cooperative purchasing alliances. Collin County Community Supervision and Corrections Department and the Texas Health and Human Services Commission are the primary recent buyers; the latter issued both a direct-to-manufacturer prescriptions RFI and participates in broader generic-pharmaceutical cooperative purchasing vehicles like MMCAP. The work being solicited includes drug-testing services requiring specimen collection and immunoassay screening with confirmation protocols (as in Collin County's RFP 2026-327), state-level pharmacy benefit program design incorporating direct manufacturer relationships, and participation in multi-state cooperative contracts for generic pharmaceuticals and OTC products distributed to government facilities across participating states.

Recent activity concentrates in Texas and Minnesota. Collin County's RFP 2026-327 for offender specimen collection and drug testing services, posted July 9, 2026 with proposals due July 23, 2026, carries an estimated contract value of $600,000 over two years with three optional one-year renewals; the procurement evaluates compliance, vendor understanding, firm qualifications, client references, and cost (30 points each for understanding and cost, 25 for qualifications, 15 for references). The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products in January 2026 with a March 26, 2026 response deadline, requiring vendor participation through AmerisourceBergen, Cardinal Health, and Morris & Dickson; evaluation weights pricing (75 percent), price competitiveness, EDI capability, and compliance with cGMP and DSCSA. The Texas Health and Human Services Commission's RFI HHS0017013, posted April 3, 2026, signals early-stage market research toward a direct-to-manufacturer prescription program but has not yet launched a formal RFP with binding timelines or budget allocation.